ADMA Biologics (ADMA) Announces Proposed $75M Share Common Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
ADMA Biologics (ADMA) Prices 23.5M Share Upsized Common Offering at $3.50/Sh
February 7, 2020 6:10 AM ESTADMA Biologics, Inc. (NASDAQ: ADMA) an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases, today announced the pricing of its previously announced underwritten public offering of 23,500,000 shares... More
After-Hours Stock Movers 02/06: (ASRT) (PINS) (UBER) Higher; (ZGNX) (MYGN) (RESN) Lower (more...)
February 6, 2020 6:01 PM ESTAfter-Hours Stock Movers
Assertio Therapeutics, Inc. (NASDAQ: ASRT) 51% HIGHER; entered into a definitive agreement (Agreement) with Collegium Pharmaceutical, Inc. (Nasdaq: COLL) pursuant to which Collegium will acquire the NUCYNTA® franchise of products from the Company. The closing of the agreement is expected by February 14, 2020.
Zogenix, Inc. (NASDAQ: ZGNX) 33% LOWER; reported positive top-line results from its global Phase 3 clinical trial (Study 1601) of its lead investigational therapy, FINTEPLA® (ZX008, fenfluramine oral solution) in... More
ADMA Biologics (ADMA) to Offer $75M in Stock
February 6, 2020 4:09 PM ESTADMA Biologics, Inc. (Nasdaq: ADMA) announced that it has commenced an $75 million underwritten public offering of its common stock. The Company intends to grant the underwriters of the offering a 30-day option to purchase up to an additional 15 percent of the number of... More
